Elevance Health Reports Strong Q3 2026 Results and Raises Full-Year Earnings Guidance
Elevance Health (ELV) reported third-quarter operating revenue of $50.4 billion, a 0.7% increase driven by higher premium yields and CarelonRx performance. Adjusted diluted EPS reached $6.99, surpassing company outlooks due to favorable benefit expenses and operating outperformance. The company's benefit expense ratio improved by 70 basis points to 90.6%, supported by Medicare Advantage and Individual ACA business segments. Following these results, management raised its full-year 2026 adjusted EPS guidance to at least $29.00 and increased the earnings baseline to at least $26.75. While Medicaid attrition led to a slight decrease in total medical membership, growth in commercial fee-based membership helped offset losses. The company also reported significant operating gains within its Carelon services and pharmacy segments.
Tickers: $ELV
Topics: earnings report EPS beat guidance increase medical membership revenue growth
Read the full article at Motley Fool
Part of the story Equinix Reports Strong Q3 2026 Results and Raises Full-Year Guidance (49 articles)